Co-Diagnostics’ (CODX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Co-Diagnostics (NASDAQ:CODX) in a research note released on Monday morning,Benzinga reports. The firm currently has a $1.50 target price on the stock. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.22) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Trading Down 0.9 %

Shares of NASDAQ:CODX opened at $1.10 on Monday. The stock’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.26. Co-Diagnostics has a 12-month low of $1.00 and a 12-month high of $2.23. The stock has a market capitalization of $35.12 million, a P/E ratio of -0.80 and a beta of -0.84.

Institutional Trading of Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. Koss Olinger Consulting LLC acquired a new position in Co-Diagnostics, Inc. (NASDAQ:CODX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned 0.19% of Co-Diagnostics as of its most recent filing with the Securities and Exchange Commission. 14.99% of the stock is currently owned by institutional investors and hedge funds.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.